Peptide Research Database

FDA decisions, clinical trials, and regulatory developments in peptide therapeutics.

Download Jabbit (App Store) Browse GLP‑1 guides

Educational only — not medical advice.

⚠️ Informational Purposes Only

This database covers research compounds and FDA-approved medications for educational purposes. Not medical advice.

FDA-Approved Therapeutics

Semaglutide FDA Approved

Ozempic, Wegovy, Rybelsus

GLP-1 RA with proven cardiovascular outcomes. SELECT trial showed 20% MACE reduction.
Tirzepatide Coming Soon

Mounjaro, Zepbound

Dual GIP/GLP-1 agonist. SURMOUNT and SURPASS program results.

Liraglutide Coming Soon

Victoza, Saxenda

Daily GLP-1 RA. First-in-class cardiovascular outcomes data.

Research Compounds

BPC-157 Not Approved

Body Protection Compound

Synthetic gastric peptide. Extensive animal research; no human clinical trials.
TB-500 Not Approved

Thymosin Beta-4 fragment

Cell migration peptide. Limited clinical development; WADA prohibited.

About This Database

Jabbit's peptide database focuses on regulatory status, clinical trial outcomes, and scientific developments rather than usage protocols. We cover:

For FDA-Approved Drugs

  • Approval history and pivotal trials
  • Cardiovascular outcomes data
  • Post-market safety updates
  • Comparative effectiveness research

For Research Compounds

  • Mechanism of action from literature
  • Preclinical study summaries
  • FDA regulatory status
  • Clinical development obstacles